Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation21-04-2022
Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor PresentationCyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Dividend Updates
Declaration of Final Dividend for FY 2021-22Cyient Limited - 532175 - Financial Results For The Quarter And Year Ended 31 March 2022
Financial Results for the quarter and year ended 31 March 2022Cyient Limited - 532175 - Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Period Ended 31 March 2022
Certificate Under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period ended 31 March 2022Cyient Limited - 532175 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under Regulation 74(5) of SEBI (LODR)Regulation,2018Cyient Limited - 532175 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 025250 Name of the Signatory :- Sudheendhra PuttyDesignation :- Company Secretary and Compliance OfficerCyient Q4 PAT may dip 4.2% QoQ to Rs. 126.1 cr: Prabhudas Lilladher
Net Sales are expected to decrease by 1.3 percent Q-o-Q (up 6.8 percent Y-o-Y) to Rs. 1,168.1 crore, according to Prabhudas Lilladher.Cyient Limited - 532175 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press ReleaseCyient Limited - 532175 - Earnings Conference Call - For The Fourth Quarter And Year Ended 31 March 2022
Earnings conference call - for the Fourth Quarter and year ended 31 March 2022Cyient Limited - 532175 - Board to consider FY22 results & Final Dividend on April 21, 2022
Cyient Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on April 21, 2022, inter alia to:1. approve and take on record the audited financial results of the Company under Indian Accounting Standards (Ind AS) for the quarter and year ended March 31, 2022;2. approve and take on record the audited consolidated financial results of the Company and its subsidiaries under Ind AS for the quarter and year ended March 31, 2022.3. Recommendation of final dividend for the financial year ended March 31, 2022, if any.